United Italian Trading Corporation

Femarelle® official launch in Singapore

24 October 2024, official launch of the Femarelle® line – Rejuvenate, Recharge, and Unstoppable – with Professor Andrea Genazzani and Dr June Tan Sheren. The Femarelle® line uses the proprietary ingredient DT56a, which works in the body in a selective manner, supporting the management of symptoms associated with hormonal changes across the different stages of a woman’s life, from peri-menopause to post-menopause. Femarelle® provides a unique non-hormonal botanical solution, that supports healthy female hormonal and mood balance, improves energy levels, and overall quality of life.

Bonjesta® official launch in Singapore

29 July 2024, official launch of Bonjesta®, with Dr Jason Lim, Professor Yariv Yogev, and A/Prof Tan Thiam Chye. Bonjesta® multilayer, extended-release tablets are designed to provide immediate and continuous relief of morning sickness symptoms throughout the day and night. The simple schedule of administration reduces pill burden and improves patient compliance.

UITC launches Anscare™ Scar Reduction Silicone Gel C+

10 January 2024, UITC launches BenQ Anscare Scar Reduction Silicone Gel C+, an advanced silicone gel formula with Vitamin C that softens and flattens both existing and new scars, like keloids and hypertrophic scars that result from surgery injury, C-section, burns, cuts, scrapes, acnes, insect bites. Available at doctors’ clinics.

UITC expands Bioflor® range with Bioflor® capsules

4 November 2023, in addition to Bioflor® sachets, UITC has also launched Bioflor® capsules, which is a more convenient dosage form for adults. Bioflor Saccharomyces boulardii CNCM I-745® is a unique yeast based probiotic drug that is paired together with antibiotics, used for the treatment and prevention of antibiotic-associated diarrhoea.

Bonjesta® regulatory approval by HSA

18 September 2023, UITC is pleased to announce regulatory approval has been obtained for Bonjesta®. Bonjesta® is a faster acting, longer lasting, optimized reformulation of Diclectin®, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

K-CAB® official launch in Singapore

31 August 2023, official launch of K-CAB®, with Professor Hwoon-Yong Jung, Professor Chandra Prakash Gyawali, and Adjunct Associate Professor David Ong. K-CAB® is a novel drug in the new P-CAB class, used for the treatment of acid-related gastrointestinal disorders. It is characterized by its rapid onset of action within 30 minutes and sustained nocturnal gastric acid control.

UITC and AFT Pharmaceuticals enters partnership for Maxigesic®

1 June 2023, With the commitment to help improve the health and well-being of people, UITC and AFT Pharmaceuticals enters partnership to expand channel distribution for Maxigesic®
AFT Pharmaceuticals is an ASX-listed company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. AFT and UITC will continue to expand the product line to build a healthier life for everyone.

UITC expands the Germidine® range with Germidine Antiseptic Solution

Germidine Antiseptic Solution

26 May 2023, Following the successful launch of Germidine Sore Throat Spray into the retail segment in March 2022, UITC now expands into the wound care space with Germidine Antiseptic Solution. Germidine provides broad antimicrobial activity and is the antiseptic of choice.

UITC appointed as the exclusive distributor of Pomi-T®

UITC Website Prototype-News&Insights-images-04_Pomi-T-white

20 February 2023, UITC has been appointed as the exclusive distributor of Pomi-T, a scientifically evaluated polyphenol-rich whole food supplement that has been studied in a UK national scientific study led by oncologist Professor Robert Thomas. Pomi-T positively influenced the rate of PSA progression among men with localised prostate cancer.

K-CAB® regulatory approval by HSA

K-CAB® regulatory approval by HSA

11 Jan 2023, UITC is pleased to announce that it has received regulatory approval for K-CAB, a new potassium competitive acid blocker drug indicated for the treatment of erosive gastroesophageal reflux disease (GERD), non-erosive gastroesophageal reflux disease (NERD), gastric ulcer (GU) and eradication of H.pylori when concurrently given with appropriate antibiotic therapy in patients with peptic ulcer and/or chronic atrophic gastritis.